Anti-Human PARC
| Code | Size | Price |
|---|
| LEI-P225-20ug | 20 ug | £199.00 |
Quantity:
| LEI-P225-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Application: Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Long Description:
The continued localization of p53 to the nucleus is essential for its function as a tumor suppressor. PARC, a large, Parkin-like ubiquitin ligase has recently been identified as a cytoplasmic anchor protein in p53-associated protein complexes. In the absence of stress, PARC inactivation results in nuclear localization of p53 and activation of p53-dependent apoptosis, while overexpression of this protein promoted cytoplasmic sequestration of p53. Surprisingly, PARC knockout mice were viable and exhibited no obvious phenotype, suggesting that other proteins, such as the highly related cullin family of E3 ubiquitin ligases, may perform similar functions in the absence of PARC. Additionally, it has been suggested that p53 binding to PARC may serve to control PARC function.
Target:
PARC
References
1. Puskas, N. et al. (2003) Cell 112:29-40. 2. DeCaprio, JA. et al. (2005) Mol. Cell. Biol. 25:5579-89.
Related Products
| Product Name | Product Code | Supplier | Anti-Human PARC (CCL18) | LEI-M172 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PARC Blocking Peptide | LEI-P226 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||